Company Profile
Forte Biosciences Stock Price, News & Analysis
- Ticker:
- FBRX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
76.50 USD (+39.65%)
Close
Last updated: July 27, 2026
372M USD
Market cap
Why the stock is moving
As of Jul 27, 2026, FBRX closed up 39.6% at $76.50. No new same-company headline was identified in the current news window.
Company overview
Business overview
Forte Biosciences is a clinical-stage biotechnology company focused on dermatology and immune-mediated disease. Its profile is built around translating immune and skin biology into differentiated therapies.
Geographic Base and Sector Classification
Forte is headquartered in the United States and listed on NASDAQ. It sits in specialty biotech with a dermatology and immunology focus.
Business Model Characteristics
The company depends on clinical progress, dose selection, and pipeline prioritization to create value. Investors usually watch proof-of-concept data and whether the company can build a differentiated immune-dermatology franchise.
Position Within the Biotechnology Landscape
Forte occupies a small but catalyst-sensitive dermatology niche within biotech. The stock is typically driven by clinical updates and the market's view of the platform's differentiation.
Future catalysts
Forte Biosciences’ catalysts are FB-102 and any dermatology / immune-disease update that shows the program still has a strong path. The market will care about whether the next data point supports the platform thesis.
Recent news
The five most recent related feed items are shown below in reverse chronological order.
- 01
Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer
KYMR · Source: Kymera
- 02
- 03
- 04
- 05
Avalo Therapeutics to Participate in the BTIG Biotechnology Conference
AVTX · Source: Avalo Therapeutics
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Forte Biosciences (FBRX)?
Forte Biosciences (FBRX) most recently closed at 76.50 USD, a +39.65% move versus the previous session.
What is the market cap of Forte Biosciences (FBRX)?
Forte Biosciences currently has a market capitalization of 372M USD on BioPharmSignal.
What does Forte Biosciences do?
Forte Biosciences is a clinical-stage biotechnology company focused on dermatology and immune-mediated disease. Its profile is built around translating immune and skin biology into differentiated therapies.
On which exchange is FBRX stock listed?
Forte Biosciences (FBRX) is associated with NASDAQ, United States, Biopharma.
What is FB-102?
Forte Biosciences’ catalysts are FB-102 and any dermatology / immune-disease update that shows the program still has a strong path.
Which conditions is Forte Biosciences targeting with FB-102?
Forte Biosciences is associated with dermatology based on its company overview and current catalyst commentary.
How does Forte Biosciences describe recent progress with FB-102?
Forte Biosciences’ catalysts are FB-102 and any dermatology / immune-disease update that shows the program still has a strong path.
What is Forte?
Forte Biosciences is a clinical-stage biotechnology company focused on dermatology and immune-mediated disease.